Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 8월 24

Amphastar Pharmaceuticals Inc

AMPHNASDAQ
Trade with Public
Trade with Public
$21.60
-0.08-0.37%
가까이에: Aug 21, 5:00 PM EST
$21.60
N/A
시간외: Aug 21, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Amphastar Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amphastar Pharma (AMPH).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

4Hold
1Sell
Consensus RatingOverweight# Analysts5Avg. Consensus PT$28Upside to Avg. PT+30.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026BarclaysGlen SantangeloPT RaiseEqual-Weight$20→$23
Aug 7, 2026Piper SandlerDavid AmsellemPT CutNeutral$21→$20
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.
Benzinga Newsdesk

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.
Avi Kapoor

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Equal-Weight and lowers the price target from $30 to $19.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved